Ricerca Biosciences Announces Strategic Collaboration With Fulcrum
Ricerca Biosciences, an integrated preclinical CRO providing services to the biopharmaceutical industry, recently announced a strategic partnership with Fulcrum Pharma, an Aptiv Solutions company, a leading provider of drug development consulting and regulatory services essential to progress a development program from research to product approval. The collaboration provides unique, value-added capabilities to biopharmaceutical companies by creating a streamlined and efficient process to move a candidate from development to clinical evaluation.
“The Fulcrum Pharma collaboration is an attractive and exciting proposition for Ricerca and our clients,” said Ian Lennox, CEO of Ricerca. “Fulcrum Pharma brings deep experience in
“The collaboration offers our early stage clients a streamlined service to move efficiently through preclinical development to creation of high-quality
Ricerca Biosciences provides the full range of preclinical services from early discovery medicinal chemistry, compound screening, profiling, and lead optimization through full drug safety, metabolism, and efficacy development support, as well as clinical supply and commercial API production capability. Fulcrum Pharma is a global leader in the provision of strategic and operational regulatory support to assist clients in the authorship and approval of regulatory submissions. Aptiv Solutions is a global biopharmaceutical and medical device development services company focused on recognizing, understanding, and enabling clients to capitalize on rapid and fundamental changes facing companies developing products in the pharmaceutical, biotech, and medical device market.
Total Page Views: 1076
